Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Adma Biologics (ADMA) Shares Outstanding (2016 - 2025)

Adma Biologics' Shares Outstanding history spans 14 years, with the latest figure at $239.8 million for Q4 2025.

  • For Q4 2025, Shares Outstanding rose 1.34% year-over-year to $239.8 million; the TTM value through Dec 2025 reached $239.8 million, up 1.34%, while the annual FY2025 figure was $239.8 million, 1.34% up from the prior year.
  • Shares Outstanding reached $239.8 million in Q4 2025 per ADMA's latest filing, roughly flat from $239.7 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $239.8 million in Q4 2025 to a low of $123.0 million in Q1 2021.
  • Average Shares Outstanding over 5 years is $209.7 million, with a median of $225.2 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding: skyrocketed 86.66% in 2021, then grew 1.34% in 2025.
  • A 5-year view of Shares Outstanding shows it stood at $195.8 million in 2021, then increased by 13.28% to $221.8 million in 2022, then grew by 1.91% to $226.1 million in 2023, then rose by 4.67% to $236.6 million in 2024, then rose by 1.34% to $239.8 million in 2025.
  • Per Business Quant, the three most recent readings for ADMA's Shares Outstanding are $239.8 million (Q4 2025), $239.7 million (Q3 2025), and $239.4 million (Q2 2025).